Trial · NCT03338621
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Culture Negative Status by 8 Weeks | Drug Sensitive-TB 2HRZE/4HR | 70 | Participants | ||
| Number of Participants With Culture Negative Status by 8 Weeks | Drug Sensitive-TB 4BPaMZ | 122 | Participants | ||
| Number of Participants With Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) at 52 Weeks From Start of Therapy (12 Months) | Drug Sensitive-TB 4BPaMZ | Favorable | 120 | Participants | |
| Number of Participants With Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) at 52 Weeks From Start of Therapy (12 Months) | Drug Sensitive-TB 2HRZE/4HR | Favorable | 134 | Participants | |
| Number of Participants With Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) at 52 Weeks From Start of Therapy (12 Months) | Drug Resistant-TB 6BPaMZ | Favorable | 111 | Participants | |
| Number of Participants With Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) at 52 Weeks From Start of Therapy (12 Months) | Drug Sensitive-TB 4BPaMZ | Unfavorable | 24 | Participants | |
| Number of Participants With Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) at 52 Weeks From Start of Therapy (12 Months) | Drug Sensitive-TB 2HRZE/4HR | Unfavorable | 10 | Participants | |
| Number of Participants With Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) at 52 Weeks From Start of Therapy (12 Months) | Drug Resistant-TB 6BPaMZ | Unfavorable | 22 | Participants | |
| Time to Culture Negative Status | Drug Sensitive-TB BPaMZ | 6 | Inter-Quartile Range 4 to 8 | weeks | |
| Time to Culture Negative Status | Drug Sensitive-TB 2HRZE/4HR | 11 | Inter-Quartile Range 6 to 12 | weeks | |
| Time to Culture Negative Status | Drug Resistant-TB BPaMZ | 5 | Inter-Quartile Range 3 to 7 | weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03338621/results